Advanced search
Publication Cover
Infection and Drug Resistance Volume 14, 2021 - Issue
Submit an article Journal homepage
82
Views
0
CrossRef citations to date
0
Altmetric
Rapid Communication

The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data

Serena Capici1 Phase 1 Research Unit, ASST Monza, Monza, Italy
,
Luca Sala1 Phase 1 Research Unit, ASST Monza, Monza, Italy
,
Stefania Galimberti2 Bicocca Bioinformatics Biostatistics and Bioimaging B4 Center, School of Medicine and Surgery, University of Milano - Bicocca, Monza, Italy
,
Maria Grazia Valsecchi2 Bicocca Bioinformatics Biostatistics and Bioimaging B4 Center, School of Medicine and Surgery, University of Milano - Bicocca, Monza, Italy
,
Nicola Squillace3 Infectious Disease Unit, ASST Monza, Monza, ItalyORCID Iconhttps://orcid.org/0000-0002-7608-6045
ORCID Icon,
Giulia Gustinetti3 Infectious Disease Unit, ASST Monza, Monza, Italy
,
Marina Elena Cazzaniga1 Phase 1 Research Unit, ASST Monza, Monza, Italy;4 School of Medicine and Surgery, University of Milano-Bicocca, Monza, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1756-6935
ORCID Icon &
Paolo Bonfanti3 Infectious Disease Unit, ASST Monza, Monza, Italy;4 School of Medicine and Surgery, University of Milano-Bicocca, Monza, ItalyORCID Iconhttps://orcid.org/0000-0001-7289-8823
ORCID Icon show all
Pages 1389-1392 | Published online: 13 Apr 2021

References

  • Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-332171076
  • Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi:10.1016/S0140-6736(20)30628-032192578
  • Quartuccio L, Sonaglia A, McGonagle D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care [published online ahead of print, 2020 May 15]. J Clin Virol. 2020;129:104444. doi:10.1016/j.jcv.2020.10444432570043
  • Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43–49. doi:10.1016/j.ejim.2020.05.02132482597
  • Colaneri M, Bogliolo L, Valsecchi P, et al. Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms. 2020;8(5):695. doi:10.3390/microorganisms8050695
  • Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. 2020;50(5):397–400. doi:10.1016/j.medmal.2020.05.00132387320
  • Cortegiani A, Ippolito M, Greco M, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology. 2021;27(1):52–66. doi:10.1016/j.pulmoe.2020.07.00332713784
  • Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333–2344. doi:10.1056/NEJMoa202883633085857
  • Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20–30. doi:10.1056/NEJMoa203034033332779
  • Perrone F, Piccirillo MC, Ascierto PA, et al. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med. 2020;18(1):405. doi:10.1186/s12967-020-02573-933087150
  • Galimberti S, Sasieni P, Valsecchi MG. A weighted Kaplan-Meier estimator for matched data with application to the comparison of chemotherapy and bone-marrow transplant in leukaemia. Stat Med. 2002;21(24):3847–3864. doi:10.1002/sim.135712483771
  • Galimberti S, Valsecchi MG. Multivariate permutation test to compare survival curves for matched data. BMC Med Res Methodol. 2013;13:16. doi:10.1186/1471-2288-13-1623399031
  • Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–e484. doi:10.1016/S2665-9913(20)30173-932835257
  • REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021. doi:10.1056/NEJMoa2100433

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.